ClinicalTrials.gg
CompletedNCT06704932Updated Jan 12, 2026

A First-in-human Study to Investigate Safety and Tolerability of SAR446959 in Participants With Osteoarthritis of the Knee

A Phase 1 interventional study of SAR446959 and Placebo in Osteoarthritis, sponsored by Sanofi. Completed at 1 site in Germany. Open to participants aged 45 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-12.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
45 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 13 studies in Osteoarthritis by Sanofi — none open to participants now, none under way, none of them phase 3. Osteoarthritis · Sanofi.

Enrollment
10th of 11
32 · median 150
Started
2024
the only one that year
Phase 1
3 of 13
none open now
Registered
13th of 13
by date

Among the 13 studies in Osteoarthritis by Sanofi, this one is the 10th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2024, is one of 3 in phase 1, and was the 13th registered.

Osteoarthritis

2,977 studies on the registry are indexed under Osteoarthritis; 437 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

None of the 13 studies in Osteoarthritis by Sanofi is open now. The open studies under Osteoarthritis, anywhere →

Who these studies take

Of the 284 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 45 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Osteoarthritis by Sanofi as a file.
02

Study summary

This is a randomized, placebo-controlled, participant- and Investigator-blinded Phase 1 study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of ascending single intra-articular doses of SAR446959 in female and male participants with osteoarthritis of the knee 45 to 65 years of age.

The anticipated study duration for each participant is approximately 28 weeks including the following study periods:

  • Screening Period: from Day -28 to Day ˗2.
  • Institutionalization Period: from Day -1 to Day 3 (dosing on Day 1).
  • End-of-Study: Day 85 ±5 days
  • Post-treatment Observation Period: from Day 1 to Day 85 ±5 days after SAR446959 or Placebo injection (including 8 visits).
  • Follow-up Period: from the day after End-Of-Study Visit to Day 169 ±5 days (including 2 follow-up phone calls and 1 follow-up visit).
03

Conditions studied

  • Osteoarthritis

Browse trials for

04

Who can participate

Ages eligible
45 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Participants must have a diagnosis of primary knee osteoarthritis, based on the American College of Rheumatology Clinical criteria using history and physical examination in the index knee

  • Participants must have index knee OA symptoms since at least 6 months before screening.
  • Participant must have a Kellgren-Lawrence grade of 1-3 in the tibio-femoral compartment in the index knee confirmed by radiography in standing weight-bearing fixed flexion position and posterior-anterior view at screening or within 6 months before screening.
  • Participant must have a KOOS Pain subscale score of at least 25 and a maximum of 75 (on 0-100 score) at screening.

Vital signs after 10 minutes resting in supine position at screening within the following ranges:

  • 95 mmHg \<systolic blood pressure (SBP) \<140 mmHg
  • 45 mmHg \<diastolic blood pressure (DBP) \<90 mmHg
  • 50 bpm \<heart rate (HR) \<100 bpm

    • Standard 12-lead (ECG) parameters after 10 minutes resting in supine position at screening in the following ranges; 120 ms\<PR\<220 ms, 50 bpm \<heart rate (HR) \<100 bpm; QRS\<120 ms, (Fridericia algorithm recommended) ≤450 ms and normal ECG tracing unless the Investigator considers an ECG tracing abnormality to be not .
    • At Screening and Day- 1, laboratory parameters within the normal range (or defined screening threshold for the Investigator site), unless the Investigator considers an abnormality to be clinically irrelevant for the participant. Hepatic transaminases (, alanine aminotransferase) should not exceed 1.5 × the upper laboratory normal. Total value up to 1.5-fold the upper normal limit can be acceptable if associated with normal conjugated bilirubin value (unless the participant has documented Gilbert syndrome).
    • Participant must have a (BMI) \<35 kg/m2.

Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply:

  • Participant with severe Hoffa-synovitis or large effusion-synovitis at screening.
  • Participant with past joint replacement surgery of the index knee or participant is expected to have knee replacement within the upcoming 6 months after enrollment.
  • Participant with anterior cruciate ligament tears in the index knee.
  • Participant with destabilizing meniscal tears (ie, root tears) or meniscus extrusion of >5 mm in the index knee.
  • Participant with a history or presence of (as identified by MRI at screening), osteonecrosis, subchondral insufficiency fracture, atrophic osteoarthritis, large subchondral cysts, osteoporosis, osteomalacia of the appendicular bones, rapidly progressing osteoarthritis (RPOA) Type I or Type II or accelerated knee OA (AKOA), pathologic fracture, bone bruise, primary or tumor, malignant bone marrow infiltration, joint infection, in the index knee.
  • Participant with concurrent medical or arthritic conditions that could interfere with evaluation of the index knee joint including, diseases, metabolic diseases, gout/pseudogout, hemochromatosis, acromegaly, fibromyalgia, rheumatoid arthritis, Paget's disease, Ehlers-Danlos Syndrome, Gaucher's disease, Stickler's syndrome, joint infection, haemophilia, haemochromatosis, neuropathic arthropathy or other inflammatory arthropathies in any joint.
  • Participant with documented significant malalignment of the anatomical axis (medial angle formed by the femur and tibia) of the target knee as assessed by visual inspection of the lower limb by an orthopedist.
  • Presence of surgical hardware or other foreign bodies in the index knee.
  • Participant had IA injections to any knee within 3 months prior to inclusion or planned within the study period, including but not limited to , hyaluronic acid, blood-derived cell concentrates, gene therapies, or human serum albumin.
  • Participant with a history of significant trauma or surgery (eg., open or arthroscopic) within 12 months prior to screening.
  • Participant with clinical hip osteoarthritis or hip prosthesis recently implanted (within 1 year prior to screening) on the side of the index knee or hip replacement on either side planned within the study period.
  • Coronary stent within past 6 months, unstable ischemic heart disease, including acute myocardial infarction within past 1 year prior to screening or unstable angina in the 6 months prior to screening or during the screening period.
  • Cardiomyopathy, as defined by Stage III-IV () cardiac failure, or other relevant cardiovascular disorder that in the investigator's judgement may put participant at risk.
  • Abnormal laboratory test(s) at Screening
  • Participant is bound to use a wheelchair or walking frame, or participant is bed bound.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    SAR446959

    Participants will receive a single intra-articular dose of SAR446959 on Day 1

    Drug: SAR446959

  • Placebo comparator
    Placebo

    Participants will receive a single intra-articular dose of placebo on Day 1. The injection volume of the placebo will be the same as the injection volume for SAR446959 in the corresponding dose level cohort.

    Drug: Placebo

Interventions

  • DrugSAR446959

    Pharmaceutical form:solution for injection-Route of administration:Intra-articular injection

  • DrugPlacebo

    Pharmaceutical form:solution for injection-Route of administration:Intra-articular injection

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs)/treatment emergent adverse events (TEAEs) including injection site reactions

    Assessment of adverse events (AE) / treatment-emergent adverse events (TEAE).

    Time frame: Day 1 up to the end-of-study visit (Day 85)

  2. Number of participants with potentially clinically significant abnormalities (PCSAs)

    Count of PCSAs and descriptive statistics will be done on clinical laboratory, vital signs and 12-Lead ECG parameters.

    Time frame: Day 1 up to the end-of-study visit (Day 85)

Secondary outcomes

  1. Pharmacokinetic (PK) parameter of SAR446959: Cmax

    Cmax: Maximum plasma concentration observed

    Time frame: Day 1 up to the follow up visit (Day 169)

  2. PK parameter of SAR446959: AUClast

    AUClast: Area under the plasma concentration versus time curve calculated using the trapezoidal method from time zero to the real time

    Time frame: Day 1 up to the follow up visit (Day 169)

  3. PK parameter of SAR446959: AUC

    AUC: Area under the plasma concentration versus time curve extrapolated to infinity

    Time frame: Day 1 up to the follow up visit (Day 169)

  4. PK parameter of SAR446959: Tmax

    Tmax: Time to reach Cmax

    Time frame: Day 1 up to the follow up visit (Day 169)

  5. PK parameter of SAR446959: t1/2z

    t1/2z:

    Time frame: Day 1 up to the follow up visit (Day 169)

  6. Incidence of participants with presence of anti-drug antibodies (ADA) against SAR446959 in the systemic circulation.

    Time frame: Day 1 up to the follow up visit (Day 169)

07

Study locations

1 site
  • Investigational Site Number : 2760001
    Berlin, 14050, Germany
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Dec 2025, 12 months.

Of 35 industry-sponsored phase 1 interventional studies under Osteoarthritis, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's 12 months is close to that.

Counting every sponsor, half of 58 studies reached it within 20 months; a quarter within 9 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2024
First posted
Nov 26, 2024
StartActual
Nov 20, 2024
Primary completionActual
Dec 18, 2025
CompletionActual
Dec 18, 2025
Last update
Jan 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06704932
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Nov 26, 2024
Start date
Nov 20, 2024
Primary completion
Dec 18, 2025
Completion
Dec 18, 2025
Last update
Jan 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion